Tetrandrine blocks cardiac hypertrophy by disrupting reactive oxygen species-dependent ERK1/2 signalling

British Journal of Pharmacology

Volumn 159, Issue 4, 2010, Pages 970-981

  Shen, Di Fei ^a,b   Tang, Qi Zhu ^a,b   Yan, Ling ^a,b   Zhang, Yan ^a,b   Zhu, Li Hua ^a,b   Wang, Lang ^a,b   Liu, Chen ^c   Bian, Zhou Yan ^a,b   Li, Hongliang ^a,b  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b WUHAN UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY   (China)

Author keywords

Cardiac hypertrophy; Mitogen activated protein kinase; Nuclear factor B; Reactive oxygen species; Tetrandrine; Transcription factor

Indexed keywords

ALPHA ACTIN; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CALCINEURIN; CASPASE 3; CASPASE 8; CASPASE 9; CONNECTIVE TISSUE GROWTH FACTOR; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE (NADP); I KAPPA B ALPHA; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MONOCYTE CHEMOTACTIC PROTEIN 1; MYOSIN HEAVY CHAIN; PROTEIN BAD; PROTEIN BAX; PROTEIN BNIP3; REACTIVE OXYGEN METABOLITE; TETRANDRINE; TRANSCRIPTION FACTOR NFAT3; TROPOMYOSIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DNA BINDING; ECHOCARDIOGRAPHY; ENZYME ACTIVATION; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; HEART FUNCTION; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE OVERLOAD; HEART WEIGHT; LUNG WEIGHT; MOUSE; NEWBORN; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; RAT; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TREATMENT DURATION;

ADMINISTRATION, ORAL; ANIMALS; ANIMALS, NEWBORN; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; APOPTOSIS; BENZYLISOQUINOLINES; CARDIOMEGALY; CARDIOTONIC AGENTS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; FIBROSIS; HEART FAILURE; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MYOCYTES, CARDIAC; NF-KAPPA B; NFATC TRANSCRIPTION FACTORS; PHOSPHORYLATION; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; RECOVERY OF FUNCTION; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION; VENTRICULAR FUNCTION, LEFT;

EID: 77249149414     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00605.x     Document Type: Article

References (43)

1. Ago T, Liu T, Zhai P, Chen W, Li H, Molkentin JD et al. (2008). A redox-dependent pathway for regulating class II HDACs and cardiac hypertrophy. Cell 133 : 978 993.
2. Akki A, Zhang M, Murdoch C, Brewer A, Shah AM (2009). NADPH oxidase signaling and cardiac myocyte function. J Mol Cell Cardiol 47 : 15 22.
3. Barbato R, Menabò R, Dainese P, Carafoli E, Schiaffino S, Di Lisa F (1996). Binding of cytosolic proteins to myofibrils in ischemic rat hearts. Circ Res 78 : 821 828.
4. Barry SP, Davidson SM, Townsend PA (2008). Molecular regulation of cardiac hypertrophy. Int J Biochem Cell Biol 40 : 2023 2039.
5. Bian Z, Cai J, Shen DF, Chen L, Yan L, Tang Q et al. (2008). Cellular repressor of E1A-stimulated genes attenuates cardiac hypertrophy and fibrosis. J Cell Mol Med 13 : 1302 1313.
6. Cai J, Yi FF, Bian ZY, Shen DF, Yang L, Yan L et al. (2009a). Crocetin protects against cardiac hypertrophy by blocking MEK-ERK1/2 signalling pathway. J Cell Mol Med 13 : 909 925.
7. Cai J, Yi FF, Yang L, Shen DF, Yang Q, Li A et al. (2009b). Targeted expression of receptor-associated late transducer inhibits maladaptive hypertrophy via blocking epidermal growth factor receptor signaling. Hypertension 53 : 539 548.
8. Canton M, Neverova I, Menabò R, Van Eyk J, Di Lisa F (2004). Evidence of myofibrillar protein oxidation induced by postischemic reperfusion in isolated rat hearts. Am J Physiol Heart Circ Physiol 286 : H870 H877.
9. Canton M, Skyschally A, Menabò R, Boengler K, Gres P, Schulz R et al. (2006). Oxidative modification of tropomyosin and myocardial dysfunction following coronary microembolization. Eur Heart J 27 : 875 881.
10. Chen H, Chen SC, Zhang TH, Tian HC, Guan Y, Su DF (1993). Protective effects of silybin and tetrandrine on the outcome of spontaneously hypertensive rats subjected to acute coronary artery occlusion. Int J Cardiol 41 : 103 108.
11. Chen LY, Chen X, Tian XL, Yu XH (2000). Effects of tetrandrine on calcium transport, protein fluorescences and membrane fluidity of sarcoplasmic reticulum. Br J Pharmacol 131 : 530 536.
12. Chen Y, Chen JC, Tseng SH (2007). Tetrandrine suppresses tumor growth and angiogenesis of gliomas in rats. Int J Cancer 124 : 2260 2269.
13. Clerk A, Cullingford TE, Fuller SJ, Giraldo A, Markou T, Pikkarainen S et al. (2007). Signaling pathways mediating cardiac myocyte gene expression in physiological and stress responses. J Cell Physiol 212 : 311 322.
14. Dalla Libera L, Ravara B, Gobbo V, Danieli Betto D, Germinario E, Angelini A et al. (2005). Skeletal muscle myofibrillar protein oxidation in heart failure and the protective effect of Carvedilol. J Mol Cell Cardiol 38 : 803 807.
15. Dhalla NS, Saini-Chohan HK, Rodriguez-Leyva D, Elimban V, Dent MR, Tappia PS (2009). Subcellular remodelling may induce cardiac dysfunction in congestive heart failure. Cardiovasc Res 81 : 429 438.
16. Dorn GW 2nd. (2009). Novel pharmacotherapies to abrogate postinfarction ventricular remodeling. Nat Rev Cardiol 6 : 283 291.
17. Duncan JG, Ravi R, Stull LB, Murphy AM (2005). Chronic xanthine oxidase inhibition prevents myofibrillar protein oxidation and preserves cardiac function in a transgenic mouse model of cardiomyopathy. Am J Physiol Heart Circ Physiol 289 : H1512 H1518.
18. Fang LH, Zhang YH, Ma JJ, Du GH, Ku BS, Yao HY et al. (2004). Inhibitory effects of tetrandrine on the serum- and platelet-derived growth factor-BB-induced proliferation of rat aortic smooth muscle cells through inhibition of cell cycle progression, DNA synthesis, ERK1/2 activation and c-fos expression. Atherosclerosis 174 : 215 223.
19. Feng D, Mei Y, Wang Y, Zhang B, Wang C, Xu L (2008). Tetrandrine protects mice from concanavalin A-induced hepatitis through inhibiting NF-kappaB activation. Immunol Lett 121 : 127 133.
20. Hall G, Hasday JD, Rogers TB (2006). Regulating the regulator: NF-kappaB signaling in heart. J Mol Cell Cardiol 41 : 580 591.
21. Ho LJ, Juan TY, Chao P, Wu WL, Chang DM, Chang SY et al. (2004). Plant alkaloid tetrandrine downregulates IkappaBalpha kinases-IkappaBalpha-NF-kappaB signaling pathway in human peripheral blood T cell. Br J Pharmacol 143 : 919 927.
22. Hsu YC, Chiu YT, Lee CY, Wu CF, Huang YT (2006). Anti-fibrotic effects of tetrandrine on bile-duct ligated rats. Can J Physiol Pharmacol 84 : 967 976.
23. Jenkins CM, Cedars A, Gross RW (2009). Eicosanoid signalling pathways in the heart. Cardiovasc Res 82 : 240 249.
24. Kwan CY, Achike FI (2002). Tetrandrine and related bis-benzylisoquinoline alkaloids from medicinal herbs: cardiovascular effects and mechanisms of action. Acta Pharmacol Sin 23 : 1057 1068.
25. Li HL, Wang AB, Huang Y, Liu DP, Wei C, Williams GM et al. (2005). Isorhapontigenin, a new resveratrol analog, attenuates cardiac hypertrophy via blocking signaling transduction pathways. Free Radic Biol Med 38 : 243 257.
26. Li HL, Huang Y, Zhang CN, Liu G, Wei YS, Wang AB et al. (2006). Epigallocathechin-3 gallate inhibits cardiac hypertrophy through blocking reactive oxidative species-dependent and -independent signal pathways. Free Radic Biol Med 40 : 1756 1775.
27. Li HL, She ZG, Li TB, Wang AB, Yang Q, Wei YS et al. (2007a). Overexpression of myofibrillogenesis regulator-1 aggravates cardiac hypertrophy induced by angiotensin II in mice. Hypertension 49 : 1399 1408.
28. Li HL, Zhuo ML, Wang D, Wang AB, Cai H, Sun LH et al. (2007b). Targeted cardiac overexpression of A20 improves left ventricular performance and reduces compensatory hypertrophy after myocardial infarction. Circulation 115 : 1885 1894.
29. Liou JT, Chen ZY, Ho LJ, Yang SP, Chang DM, Liang CC et al. (2008). Differential effects of triptolide and tetrandrine on activation of COX-2, NF-kappaB, and AP-1 and virus production in dengue virus-infected human lung cells. Eur J Pharmacol 589 : 288 298.
30. Luo JD, Xie F, Zhang WW, Ma XD, Guan JX, Chen X (2001). Simvastatin inhibits noradrenaline-induced hypertrophy of cultured neonatal rat cardiomyocytes. Br J Pharmacol 132 : 159 164.
31. McCubrey JA, Bäsecke J, Cervello M, Martelli AM, Franklin RA (2008). GSK-3beta is a critical mediator of tetrandrine induced cell cycle arrest and cytotoxicity. Cancer Biol Ther 7 : 1079.
32. Machackova J, Barta J, Dhalla NS (2006). Myofibrillar remodeling in cardiac hypertrophy, heart failure and cardiomyopathies. Can J Cardiol 22 : 953 968.
33. Molkentin JD (2004). Calcineurin-NFAT signaling regulates the cardiac hypertrophic response in coordination with the MAPKs. Cardiovasc Res 63 : 467 475.
34. Olson EN (2004). A decade of discoveries in cardiac biology. Nat Med 10 : 467 474.
35. Rao MR (2002). Effects of tetrandrine on cardiac and vascular remodeling. Acta Pharmacol Sin 23 : 1075 1085.
36. Schulz RA, Yutzey KE (2004). Calcineurin signaling and NFAT activation in cardiovascular and skeletal muscle development. Dev Biol 266 : 1 16.
37. Tang Q, Cai J, Shen D, Bian Z, Yan L, Wang YX et al. (2009). Lysosomal cysteine peptidase cathepsin L protects against cardiac hypertrophy through blocking AKT/GSK3beta signaling. J Mol Med 87 : 249 260.
38. Vega RB, Bassel-Duby R, Olson EN (2003). Control of cardiac growth and function by calcineurin signaling. J Biol Chem 278 : 36981 36984.
39. Wang G, Lemos JR, Iadecola C (2004). Herbal alkaloid tetrandrine: fron an ion channel blocker to inhibitor of tumor proliferation. Trends Pharmacol Sci 25 : 120 123.
40. Xu Y, Rao MR (1995). Effects of tetrandrine on left ventricle hypertrophy in deoxycorticosterone acetate-salt hypertensive rats. Eur J Pharmacol 278 : 1 7.
41. Yao WX, Jiang MX (2002). Effects of tetrandrine on cardiovascular electrophysiologic properties. Acta Pharmacol Sin 23 : 1069 1074.
42. Yin MF, Lian LH, Piao DM, Nan JX (2007). Tetrandrine stimulates the apoptosis of hepatic stellate cells and ameliorates development of fibrosis in a thioacetamide rat model. World J Gastroenterol 13 : 1214 1220.
43. Yoshioka J, Imahashi K, Gabel SA, Chutkow WA, Burds AA, Gannon J et al. (2007). Targeted deletion of thioredoxin-interacting protein regulates cardiac dysfunction in response to pressure overload. Circ Res 101 : 1328 1338.